{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.05","value":"1.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Change from baseline in Hematology laboratory analysis. Includes Hemoglobin. Baseline is the last observation collected prior to or on the date of product infusion.","dispersionType":"Standard Deviation","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"MEAN","populationDescription":"All participants who received at least one JCAR017 infusion evaluable for hematology laboratory tests","reportingStatus":"POSTED","timeFrame":"Baseline and Day 29","title":"Change From Baseline of Hematology Laboratory Results: Hemoglobin","type":"SECONDARY","unitOfMeasure":"g/L"}